ROXIAM CAPSULES 150MG

N05AL04(WHO) Withdrawn 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide 80125-14-0N 54477 DB00409Y 49195Y 0223RD59PE D02683Y ChEMBL22242Y DTXSID6045668 Interactive image CCN2CCC[C@H]2CNC(=O)c1c(OC)ccc(Br)c1OC InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1YKey:GUJRSXAPGDDABA-NSHDSACASA-NY Remoxipride(Roxiam) is anatypical antipsychotic(although according to some sources it is atypical antipsychotic) which was previously used inEuropefor the treatment ofschizophreniaand acutemaniabut was withdrawn due totoxicityconcerns (incidence ofaplastic anemiain 1/10,000 patients).It was initially launched byAstraZenecain 1990 and suspension of its use began in 1993.Remoxipride acts as aselectiveD2andD3receptorantagonistand also has highaffinityfor thesigma receptor, possibly playing a role in its atypical neuroleptic action. Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.There was some interest in its use in the treatment of treatment-resistant schizophrenia.